Sinusoidal obstruction syndrome overview

Jump to navigation Jump to search

Sinusoidal obstruction syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sinusoidal obstruction syndrome from Other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sinusoidal obstruction syndrome overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sinusoidal obstruction syndrome overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sinusoidal obstruction syndrome overview

CDC on Sinusoidal obstruction syndrome overview

Sinusoidal obstruction syndrome overview in the news

Blogs on Sinusoidal obstruction syndrome overview

Directions to Hospitals Treating Sinusoidal obstruction syndrome

Risk calculators and risk factors for Sinusoidal obstruction syndrome overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:


Overview

Historical Perspective

Hepatic veno-occlusive disease or sinusoidal obstruction syndrome was first described in 1905 as endophelibitis of the terminal hepatic veins. Ionizing radiations as a cause of sinusoidal obstruction syndrome was identified in the 1960's and bone marrow transplant in the 1970's. However, sinusoidal obstruction syndrome or hepatic veno-occlusive disease was a well-established concept by the mid-1960's.

Classification

There is no established system for the classification of sinusoidal obstruction syndrome. However, it can be classified on the basis of severity as mild, moderate and severe.

Pathophysiology

The development of sinusoidal obstruction syndrome begins with the injury to hepatic venous endothelium. It is thought that preexisting liver disease increases the risk of developing sinusoidal obstruction syndrome (SOS) due to impairment of drug metabolism which predisposes to the endothelial injury. The endothelial cells in patients with hepatitis may have abnormal expression of adhesion molecules and procoagulant factors. The deposition of fibrinogen and factor VIII within the sinusoids leads to their dilation and congestion by erythrocytes. The progressive occlusion of venules leads to widespread zonal liver disruption and centrilobular hemorrhagic necrosis. Hepatic sinusoidal obstruction syndrome (SOS) is mainly seen in patients of hematopoietic cell transplantation.

Causes

The most common cause of sinusoidal obstruction syndrome is hematopoietic cell transplantation. Other less common causes include chemotherapeutic agents and pyrrolizidine alkaloids.

Differentiating Sinusoidal obstruction syndrome from Other Diseases

The differential diagnosis of sinusoidal obstruction syndrome includes other causes of hepatic failure that may have abnormal liver function tests such as increased conjugated bilirubin and alkaline phosphatase or a clinical presentation as right upper quadrant abdominal pain, jaundice or ascites.

Epidemiology and Demographics

The incidence of sinusoidal obstruction syndrome depends on the presence of risk factors, chemotherapy regimen and the clinical criteria used for the diagnosis. The incidence after allogeneic hematopoietic cell transplant ranges from a low of 10,000 persons per 100,000 persons to a high of 15,000 persons per 100,000 persons. The incidence of sinusoidal obstruction syndrome after autologous hematopoietic cell transplant is below 5,000 persons per 100,000 persons.

Risk Factors

Common risk factors in the development of sinusoidal obstruction syndrome are stem cell transplantation, preexisting liver dysfunction and high-dose conditioning regimens.

Screening

There is insufficient evidence to recommend routine screening for sinusoidal obstruction syndrome.

Natural History, Complications, and Prognosis

Patients with a mild or moderate form of sinusoidal obstruction syndrome require no specific therapy and can be managed with supportive care alone.The mild and moderate form of sinusoidal obstruction syndrome has a good prognosis. If left untreated, the severe form of sinusoidal obstruction syndrome is characterized by high mortality and progression to multiorgan failure.

Diagnosis

History and Symptoms

Physical Examination

Features of VOD include weight gain, tender hepatomegaly, ascites, and increased bilirubin. It often is associated with renal failure.

Laboratory Findings

Diagnosic Criteria

Imaging Findings

Ultrasound

Hepatic doppler ultrasound is typically utilized to confirm or suggest the diagnosis. Most common findings on liver doppler ultrasound include increased phasicity of portal veins with eventual development of portal flow reversal. The liver is usually enlarged but maintained normal echogenicity. A liver biopsy is required for a definitive diagnosis.

Other Diagnostic Studies

Treatment

Medical Therapy

Treatment for VOD is primarily supportive. In the BMT setting, defibrotide is an investigational treatment that may be promising. Defibrotide is a polydeoxyribonucleotide isolated from pig intestine. Although its mechanism of action in VOD is unclear, the drug is believed to have antithrombotic properties. In August 2009, Gentium S.p.A., which sponsored the phase 3 clinical trial (pivotal) of defibrotide in hepatic VOD, announced disappointing results. Further clinical development of defibrotide for this indication is uncertain.

Surgery

Prevention

See also

References

Template:WS Template:WH